The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
FDA Approval of Remdesivir — A Step in the Right Direction
Open accessAbstract
secretary of health and human services declared a public health emergency in response to Covid-19.This disease, caused by the SARS-CoV-2 virus, can have severe manifestations, including pneumonia, respiratory failure, multiorgan failure, and death.Although there is now an extensive global search for therapies, there remains an unmet need for safe and effective treatment options for patients.On May 1, 2020, on the basis of preliminary results from phase 3 trials, the Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) to allow the use of remdesivir for the treatment of suspected or laboratory-confirmed Covid-19 in adult and pediatric patients hospitalized with severe disease. 1 The scope of the EUA was subsequently expanded on August 28, to allow use in a broader hospitalized population.On October 22, the FDA approved remdesivir for use in adults and pediatric patients (12 years of age or older and weighing at least 40 kg) for the treatment of Covid-19 requiring hospitalization. 2 This approval was based largely on the results of three phase 3 clinical trials in hospitalized patients with disease of varying severity.These were the Adaptive
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Remdesivir for the Treatment of Covid-19 — Final Report
Beigel, J. H., Tomashek, K. M., Dodd, L. E., Mehta, A. K., Zingman, B. S., Kalil, A. C., Hohmann, E., Chu, H. Y., Luetkemeyer, A., Kline, S., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2007764 · Cited by 7,267
Remdesivir for 5 or 10 Days in Patients with Severe Covid-19
Goldman, J. D., Lye, D. C. B., Hui, D. S., Marks, K. M., Bruno, R., Montejano, R., Spinner, C. D., Galli, M., Ahn, M.-Y., Nahass, R. G., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2015301 · Cited by 1,362
Cited by
Tofacitinib in Patients Hospitalized with Covid-19 Pneumonia
Guimarães, P. O., Quirk, D., Furtado, R. H., Maia, L. N., Saraiva, J. F., Antunes, M. O., Kalil Filho, R., Junior, V. M., Soeiro, A. M., Tognon, A. P., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2101643 · Cited by 435
Pan, H., Peto, R., Henao Restrepo, A. M., Preziosi, M.-P., Sathiyamoorthy, V., Karim, Q. A., Alejandria, M., Hernàndez García, C., Kieny, M.-P., Malekzadeh, R., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)00519-0 · Cited by 394
Inflammasome activation at the crux of severe COVID-19
Vora, S. M., Lieberman, J., & Wu, H. (2021) · Nature Reviews Immunology · doi:10.1038/s41577-021-00588-x · Cited by 325
Hassanipour, S., Arab-Zozani, M., Amani, B., Heidarzad, F., Fathalipour, M., & Martinez-de-Hoyo, R. (2021) · Scientific Reports · doi:10.1038/s41598-021-90551-6 · Cited by 264
Metadata
- Authors
- Rubin, D., Chan-Tack, K., Farley, J., & Sherwat, A.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-12-31
- Volume
- 383
- Issue
- 27
- Pages
- 2598-2600
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3106878713
- Cited by
- 212
- References
- 2
- FWCI
- 5.37
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: FDA Approval of Remdesivir — A Step in the Right Direction. https://app.cochat.ai/papers/10.1056/nejmp2032369
- The paper
- Rubin, D., Chan-Tack, K., Farley, J., & Sherwat, A. (2020). FDA Approval of Remdesivir — A Step in the Right Direction. New England Journal of Medicine. https://doi.org/10.1056/nejmp2032369
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.